Scaffold selection and scaffold hopping in lead generation: a medicinal chemistry perspective.

Hit selection and lead generation are crucial for the success of the resource-demanding lead-optimization phase in drug discovery, and represent a major research area of medicinal chemistry today. Ligand-binding efficiency, ligand complexity, ligand-target profile complementarity and chemical tractability are important parameters in hit selection. As synthesis and assay throughput improve, a large number of analogs based on the same scaffold can be rapidly synthesized and tested. Consequently, more chemistry resources could be devoted to scaffold modifications to expand the candidate pool in lead generation. Most recently discovered druggable targets are promiscuous toward lipophilic ligands, and the hydrophobic portions of hit compounds should be preferentially modified in analog and scaffold design.

[1]  J. Deisenhofer,et al.  Structural Mechanism for Statin Inhibition of HMG-CoA Reductase , 2001, Science.

[2]  Gang Liu,et al.  Discovery and structure-activity relationship of oxalylarylaminobenzoic acids as inhibitors of protein tyrosine phosphatase 1B. , 2003, Journal of medicinal chemistry.

[3]  G. Bemis,et al.  The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.

[4]  Tudor I. Oprea,et al.  The Design of Leadlike Combinatorial Libraries. , 1999, Angewandte Chemie.

[5]  E. De Clercq,et al.  The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. , 1998, Antiviral research.

[6]  T. Chou,et al.  On the remarkable antitumor properties of fludelone: how we got there. , 2005 .

[7]  Peter Ertl,et al.  Relationships between Molecular Complexity, Biological Activity, and Structural Diversity , 2006, J. Chem. Inf. Model..

[8]  E. Freire,et al.  ITC in the post-genomic era...? Priceless. , 2005, Biophysical chemistry.

[9]  Andrew M Davis,et al.  Components of successful lead generation. , 2005, Current topics in medicinal chemistry.

[10]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[11]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[12]  Jordi Mestres,et al.  Identification of "latent hits" in compound screening collections. , 2003, Journal of medicinal chemistry.

[13]  Andreas Steinmeyer,et al.  The Hit‐to‐Lead Process at Schering AG: Strategic Aspects , 2006, ChemMedChem.

[14]  John A. Lowe,et al.  A guide to drug discovery: The role of the medicinal chemist in drug discovery — then and now , 2004, Nature Reviews Drug Discovery.

[15]  David J. Craik,et al.  FUNCTIONAL GROUP CONTRIBUTIONS TO DRUG-RECEPTOR INTERACTIONS , 1985 .

[16]  P. Hajduk,et al.  Isoxazole carboxylic acids as protein tyrosine phosphatase 1B (PTP1B) inhibitors. , 2004, Bioorganic & medicinal chemistry letters.

[17]  Jonas Boström,et al.  Computational chemistry-driven decision making in lead generation. , 2006, Drug discovery today.

[18]  Andrew R. Leach,et al.  Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..

[19]  P. Hajduk,et al.  Druggability indices for protein targets derived from NMR-based screening data. , 2005, Journal of medicinal chemistry.

[20]  E. Freire,et al.  Binding thermodynamics of statins to HMG-CoA reductase. , 2005, Biochemistry.

[21]  H. Sham,et al.  Discovery of tetralin carboxamide growth hormone secretagogue receptor antagonists via scaffold manipulation. , 2004, Journal of medicinal chemistry.

[22]  John P. Overington,et al.  Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.

[23]  Erik De Clercq,et al.  The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection , 1998 .

[24]  J. Proudfoot.  Drugs, leads, and drug-likeness: an analysis of some recently launched drugs. , 2002, Bioorganic & medicinal chemistry letters.

[25]  M. Bock,et al.  Cyclopropylamino acid amide as a pharmacophoric replacement for 2,3-diaminopyridine. Application to the design of novel bradykinin B1 receptor antagonists. , 2006, Journal of medicinal chemistry.

[26]  L. Hall,et al.  Bioisosterism: Quantitation of Structure and Property Effects , 2004, Chemistry & biodiversity.

[27]  M. Stahl,et al.  Scaffold hopping. , 2004, Drug discovery today. Technologies.

[28]  J. T. Metz,et al.  Ligand efficiency indices as guideposts for drug discovery. , 2005, Drug discovery today.

[29]  Alexander Hillisch,et al.  Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits. , 2006, Drug discovery today.

[30]  Schmid,et al.  "Scaffold-Hopping" by Topological Pharmacophore Search: A Contribution to Virtual Screening. , 1999, Angewandte Chemie.

[31]  Philip M Dean,et al.  Scaffold hopping in de novo design. Ligand generation in the absence of receptor information. , 2004, Journal of medicinal chemistry.

[32]  Tudor I. Oprea,et al.  Pursuing the leadlikeness concept in pharmaceutical research. , 2004, Current opinion in chemical biology.

[33]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[34]  György M Keseru,et al.  Hit discovery and hit-to-lead approaches. , 2006, Drug discovery today.

[35]  Sandor Vajda,et al.  Characterization of protein-ligand interaction sites using experimental and computational methods. , 2006, Current opinion in drug discovery & development.

[36]  S. Danishefsky,et al.  Small molecule natural products in the discovery of therapeutic agents: the synthesis connection. , 2006, The Journal of organic chemistry.

[37]  Alexander Alanine,et al.  Lead generation--enhancing the success of drug discovery by investing in the hit to lead process. , 2003, Combinatorial chemistry & high throughput screening.